Palvella Therapeutics (NASDAQ:PVLA) Announces Quarterly Earnings Results

Palvella Therapeutics (NASDAQ:PVLA) released its quarterly earnings data on Tuesday. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13), FiscalAI reports.

Palvella Therapeutics Price Performance

PVLA opened at $117.26 on Tuesday. The company’s 50-day moving average is $104.74 and its 200 day moving average is $91.17. Palvella Therapeutics has a fifty-two week low of $18.23 and a fifty-two week high of $151.18. The firm has a market capitalization of $1.39 billion, a P/E ratio of -44.87 and a beta of -0.30.

Insider Buying and Selling

In other news, Director Elaine J. Heron bought 2,400 shares of the company’s stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $125.00 per share, with a total value of $300,000.00. Following the transaction, the director directly owned 47,812 shares in the company, valued at $5,976,500. This represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC boosted its position in Palvella Therapeutics by 8.5% in the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after purchasing an additional 70,000 shares during the last quarter. First Light Asset Management LLC increased its position in shares of Palvella Therapeutics by 30.9% during the 4th quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock valued at $74,226,000 after purchasing an additional 167,597 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after purchasing an additional 330,847 shares during the last quarter. State Street Corp raised its stake in shares of Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Palvella Therapeutics by 8.6% during the 4th quarter. Federated Hermes Inc. now owns 368,038 shares of the company’s stock worth $38,523,000 after purchasing an additional 28,991 shares during the period. 40.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PVLA shares. Raymond James Financial reissued a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. UBS Group reissued a “buy” rating and set a $143.00 price objective on shares of Palvella Therapeutics in a report on Monday, December 15th. HC Wainwright increased their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Moderate Buy” and an average price target of $195.93.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.